Abstract
Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.
Original language | English (US) |
---|---|
Article number | 17325 |
Journal | Scientific reports |
Volume | 11 |
Issue number | 1 |
DOIs | |
State | Published - Dec 2021 |
Funding
Financial support for this research from the National Science Foundation (BCS-2035114), National Institutes of Health (3UL1TR001422-06S4), and the Northwestern University Office of Research is gratefully acknowledged. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.
ASJC Scopus subject areas
- General